Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MO, USA.
Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
BioDrugs. 2019 Feb;33(1):9-14. doi: 10.1007/s40259-018-0329-7.
Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.
自埃博拉病毒发现以来已有 40 多年,过去 20 年的抗埃博拉病毒疫苗研究已取得了超过 12 种不同的候选疫苗,并进入了过去和现在的多个临床试验阶段。在这 12 种疫苗中,有 4 种候选疫苗已经或正在进行 II 期临床试验,只有 1 种完成了 III 期临床试验阶段。虽然在获得国家监管机构批准的埃博拉病毒疫苗方面取得了显著进展,但仍有一些问题没有得到解答,例如但不限于疫苗的保护免疫及其持续时间,以及对于那些有感染埃博拉病毒风险的人群的适当接种策略。